Lavipharm

Lavipharm ROE

The Return on Equity (ROE) of Lavipharm (LAVI.AT) as of Oct 24, 2026 is 10.61 %. In the previous year, Return on Equity (ROE) was 16.95 % — a change of -37.42% (lower).

ROE

10.61 %

YoY

-37.42%

Last updated:

In 2025, Lavipharm's return on equity (ROE) was 10.61 %, a -37.42% increase from the 16.95 % ROE in the previous year.

The Lavipharm ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
-6.40 EUR
Jan 1, 2019
-36.99 EUR
Jan 1, 2020
-17.60 EUR
Jan 1, 2021
-17.27 EUR
Jan 1, 2022
2.07 EUR
Jan 1, 2023
4.38 EUR
Jan 1, 2024
16.95 EUR
Jan 1, 2025
10.61 EUR
The Lavipharm ROE history
YEARROEYoY
10.61 %-37.42%
16.95 %+287.28%
4.38 %+111.43%
2.07 %-111.99%
-17.27 %-1.85%
-17.60 %-52.42%
-36.99 %+478.33%
-6.40 %-90.14%
-64.89 %+464.22%
-11.50 %-158.28%
19.73 %-80.33%
100.34 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lavipharm Stock analysis

What does Lavipharm do? Lavipharm SA manufactures and imports pharmaceuticals and veterinary products, with main categories including anti-inflammatory, asthma controlling, neurological, antiseptic, analgesic, dermatological, and gastrointestinal therapies. The company offers cosmetic products under the brands Castalia Soins Dermocosmetiques and Laviderm Active Technology for skin, face, body, scalp, and hair care. Its OTC products encompass cold and flu remedies, oral care, dermatological items, condoms, antiseptics, analgesics, laxatives, and gynecology products. The company is the parent of Lavipharm Group of Companies and previously sold HITEX, a carbon dioxide extraction subcontracting business, to Robertet SA and CODIF in January 2014. Lavipharm SA's revenue streams come from the sale of pharmaceuticals, veterinary products, cosmetics under Castalia and Laviderm, and OTC products. Pharmaceutical and veterinary products target healthcare providers and pharmacies, while cosmetics and OTC products are sold directly to consumers through retail channels. The company's brand portfolio includes Castalia Soins Dermocosmetiques, Laviderm Active Technology, and its core pharmaceutical lines, with segments defined by product categories and distribution channels. The company's primary customers are healthcare professionals and retail consumers, with pharmaceuticals distributed via pharmacies and veterinary products to animal care facilities. Cosmetic products under Castalia and Laviderm are sold to consumers for personal care, and OTC products reach consumers through general retail. The sale of HITEX to Robertet SA and CODIF in 2014 was a one-time transaction that contributed to the company's financials during that period. Lavipharm is one of the most popular companies on Eulerpool.

ROE Details

Decoding Lavipharm's Return on Equity (ROE)

Lavipharm's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Lavipharm's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Lavipharm's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Lavipharm’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Lavipharm stock

Return on Equity (ROE) of Lavipharm is 10.61 % in 2025.

Return on Equity (ROE) of Lavipharm changed from 16.95 % to 10.61 %, representing a -37.42% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Lavipharm since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Lavipharm with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Lavipharm

All Key Metrics — Lavipharm